{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5"},{"groupId":"OG001","value":"36.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"436"},{"groupId":"OG001","value":"430"}],"units":"Participants"}],"title":"BICR Assessment: ITT Population"},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5"},{"groupId":"OG001","value":"38.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"436"},{"groupId":"OG001","value":"430"}],"units":"Participants"}],"title":"Investigator Assessment: ITT Population"},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.1"},{"groupId":"OG001","value":"31.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"title":"BICR Assessment: HER2 IHC >0 <1+ Population"},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.8"},{"groupId":"OG001","value":"31.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"title":"Investigator Assessment: HER2 IHC >0 <1+ Population"}],"denoms":[{"counts":[{"groupId":"OG000","value":"436"},{"groupId":"OG001","value":"430"}],"units":"Participants"}],"description":"ORR per RECIST 1.1 assessed by BICR and Investigator was defined as the percentage of participants with at least 1 visit response of CR or PR. CR was defined as disappearance of all TLs since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \\<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.","groups":[{"description":"Participants received T-DXd 5.4 mg/kg via IV infusion every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation was met.","id":"OG000","title":"T-DXd"},{"description":"Participants received Investigator's choice single-agent chemotherapy (capecitabine 1000 or 1250 mg/m\\^2 orally twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles, paclitaxel 80 mg/m\\^2 via IV infusion qw in 3-week cycles or nab-paclitaxel 100 mg/m\\^2 via IV infusion qw for 3 weeks followed by 1-week rest period in 4-week cycles) until PD, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation was met.","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"The ITT population included all randomized participants. The HER2 IHC \\>0 \\<1+ population included subset of participants included in ITT population with HER2 IHC \\>0 \\<1+ as determined by central laboratory testing and who have had at least 24 weeks of follow-up at time of interim futility PCD. Only participants with data collected in specified categories are reported.","reportingStatus":"POSTED","timeFrame":"Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)","title":"Objective Response Rate Assessed by Blinded Independent Central Review and Investigator in the Intent-to-Treat and Human Epidermal Growth Factor Receptor 2 Immunohistochemistry >0 <1+ Population","type":"SECONDARY","unitOfMeasure":"percentage of participants"}